Corporate Medical Policy
|
|
- Tracey Bishop
- 6 years ago
- Views:
Transcription
1 Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: denosumab_prolia_xgeva 3/2011 9/2017 9/2018 9/2017 Description of Procedure or Service Receptor activator of nuclear factor-κb ligand (RANKL), a protein expressed by osteoblastic stromal cells, binds to receptor activator of nuclear factor-κb (RANK) and is the primary mediator of osteoclast differentiation, activation, and survival. RANKL is responsible for osteoclast-mediated bone resorption in a broad range of conditions. Osteoprotegerin, a soluble RANKL decoy receptor that binds RANKL, is the key endogenous regulator of the RANKL RANK pathway. Denosumab (formerly known as AMG 162, Amgen) is a fully human monoclonal antibody (IgG2) that binds to RANKL with high affinity and specificity and blocks the interaction of RANKL with RANK, mimicking the endogenous effects of osteoprotegerin. In a phase 1 dose-escalation study, a single subcutaneous injection of denosumab resulted in a dose-dependent decrease in bone resorption, as measured by changes in serum and urinary N-telopeptide, markers of osteoclastic bone resorption. Denosumab is marketed under the trade name XGEVA for the prevention of skeletal-related events in cancer patients with bone metastases from solid tumors and for treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. XGEVA is also indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. XGEVA is supplied as an injection of 120 mg denosumab/1.7 ml (70 mg/ml) solution in a single-use vial for subcutaneous injection. The same drug is marketed under the trade name Prolia for postmenopausal osteoporosis and as treatment to increase bone mass in patients with prostate and breast cancer who are on hormone ablation therapy. Prolia is supplied as a single-use prefilled syringe containing 60 mg denosumab in a 1 ml solution for subcutaneous injection. ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for denosumab when it is determined to be medically necessary because the medical criteria and guidelines shown below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit Page 1 of 7
2 design; therefore member benefit language should be reviewed before applying the terms of this medical policy. When denosumab is covered Prolia may be considered medically necessary for these conditions: Treatment of postmenopausal individuals with osteoporosis at high risk for fracture (those who have had an osteoporotic fracture, or have multiple risk factors for fracture) o AND who have failed or are unable to tolerate at least one oral bisphosphonate o OR for whom oral bisphosphonate therapy is contraindicated (including inability to swallow or to remain in an upright position after oral bisphosphonate administration) Prevention of osteoporosis in individuals receiving aromatase inhibitors (anastrozole, letrozole, exemestane) Prolia may also be considered medically necessary for: Treatment to increase bone mass in individuals at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer Treatment to increase bone mass in individuals at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer Treatment to increase bone mass in individuals with osteoporosis at high risk for fracture XGEVA may be considered medically necessary for: Prevention of skeletal-related events in individuals with bone metastases from solid tumors Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy Use of Denosumab may be considered medically necessary for clinical indications not listed above when the drug is prescribed for the treatment of cancer either: In accordance with FDA label (when clinical benefit has been established, see Policy Guidelines); OR In accordance with specific strong endorsement or support by nationally recognized compendia, when such recommendation is based on strong/high levels of evidence, and/or uniform consensus of clinical appropriateness has been reached. When denosumab is not covered Denosumab (Prolia and XGEVA ) is considered investigational for the following indications (not an all inclusive list): Multiple myeloma Osteogenesis imperfecta Primary bone sarcomas (Ewing s sarcoma and osteosarcoma) Rheumatoid arthritis Denosumab is considered investigational for cancer indications when criteria is not met regarding FDA labeling OR strong endorsement/support by nationally recognized compendia, as stated under When Denosumab is covered. Page 2 of 7
3 Policy Guidelines The same active ingredient (denosumab) is found in Prolia and XGEVA. Patients should not receive both drugs. Denosumab is contraindicated in patients with hypocalcemia. Hypocalcemia should be corrected prior to initiating denosumab therapy. Patients with creatinine clearance less than 30mL/min or receiving dialysis are at risk for hypocalcemia. Denosumab is not recommended for use in pediatric patients. There are no adequate and well-controlled studies of Prolia during pregnancy or lactation. Prolia should be used during pregnancy and lactation only if the importance of the drug to the mother justified the potential risk to the fetus/infant. Drugs prescribed for treatment of cancer in accordance with FDA label may be considered medically necessary when clinical benefit has been established, and should not be determined to be investigational as defined in Corporate Medical Policy (CMP), Investigational (Experimental) Services. Please refer to CMP Investigational (Experimental) Services for a summary of evidence standards from nationally recognized compendia. Billing/Coding/Physician Documentation Information This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at They are listed in the Category Search on the Medical Policy search page. Applicable codes: J0897, S0353, S0354 ICD-10 Codes: C00.0-C49.9, C4A.0-C4A.9, C C79.9, C7A.00-C7A.8, C7B.00-C7B.8, C80.0- C86.6, C88.2-C96.Z, D00.00-D09.9, M81.0, M81.8, T50.905, Z51.11, Z51.12, Z79.811, Z For oncology use, the cancer diagnosis code must also be included when the following codes are used: M81.0, M81.8, T50.905, Z79.811, Z BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included. Scientific Background and Reference Sources McClung MR, Lewiecki EM, Cohen SB, et al. (February 2006). Denosumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med 2006; 354: Ellis GK, Bone HG, Chlebowski R, et al. (October 2008). Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer. 26: U.S. Food and Drug Administration (FDA). FDA approves new injectable osteoporosis treatment for postmenopausal women. FDA News. Rockville, MD: FDA; June 1, Retrieved 3/23/11 from: Page 3 of 7
4 Amgen, Inc. Prolia (denosumab) injection for subcutaneous use.prescribing Information.Thousand Oaks, CA:Amgen; Retrieved 3/23/11 from: U.S. Food and Drug Administration (FDA). FDA approves Xgeva to help prevent cancer-related bone injury. FDA News. Rockville, MD: FDA; November 19, Retrieved 3/23/11 from: Amgen, Inc. Xgeva (denosumab). Prescribing Information. Thousand Oaks, CA: Amgen; Retrieved 3/23/11 from: North American Menopause Society (NAMS). Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 2010: 17(1): Amgen, Inc. Prolia (denosumab) injection for subcutaneous use. Prescribing Information. Thousand Oaks, CA:Amgen; Revised 9/2011. Retrieved 9/20/11 from: Medical Director review October 2011 U.S. Food and Drug Administration (FDA). FDA granted approval for denosumab (Prolia, Amgen Inc.) as a treatment to increase bone mass in patients at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer or adjuvant aromatase inhibitor (AI) therapy for breast cancer. Retrieved 7/11/12 from 0.htm Specialty Matched Consultant Advisory Panel 9/2012. National Institutes of Health (NIH). Clinical Trial # NCT Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis - The ADAMO Trial. Retrieved from U.S. Food and Drug Administration (FDA). Supplement Approval Letter September 20, Approval of clinical indication for the treatment to increase bone mass in men with osteoporosis at high risk of fracture. Retrieved from Medical Director review 9/2012 U.S. Food and Drug Administration (FDA). FDA approves Xgeva to treat giant cell tumor of the bone. Retrieved 6/17/13 from Amgen, Inc. Xgeva (denosumab). Prescribing Information. Thousand Oaks, CA: Amgen; Retrieved 6/17/13 from: Medical Director review 6/2013 Specialty Matched Consultant Advisory Panel 9/2013 Amgen, Inc. Xgeva (denosumab). Prescribing Information. Thousand Oaks, CA: Amgen; Retrieved 9/5/14 from: Page 4 of 7
5 Specialty Matched Consultant Advisory Panel 9/2014 Amgen, Inc. Xgeva (denosumab). Prescribing Information. Thousand Oaks, CA: Amgen; Retrieved 12/9/14 from: Amgen, Inc. Prolia (denosumab) injection for subcutaneous use. Prescribing Information. Thousand Oaks, CA:Amgen; Revised 6/2014. Retrieved 12/12/14 from: Amgen, Inc. Xgeva (denosumab). Prescribing Information. Thousand Oaks, CA: Amgen; Revised 6/2015. Retrieved 8/21/15 from: Amgen, Inc. Prolia (denosumab) injection for subcutaneous use. Prescribing Information. Thousand Oaks, CA:Amgen; Revised 2/2015. Retrieved 8/21/15 from: Specialty Matched Consultant Advisory Panel 9/2015 Medical Director review 6/2016 Medical Director review 9/2016 Senior Medical Director review 2/2017 Policy Implementation/Update Information 7/1/2011 New policy developed. BCBSNC will provide coverage for denosumab when it is determined to be medically necessary because the medical criteria and guidelines outlined in the policy are met. Prolia may be considered medically necessary for treatment of postmenopausal women with osteoporosis at high risk for fracture. XGEVA may be considered medically necessary for prevention of skeletal-related events in patients with bone metastases from solid tumors. Notification given 7/1/2011 for effective date 9/29/2011. (adn) 10/1/2011 Added the following to Prolia in the When Denosumab Is Covered section: Prolia may be considered medically necessary for members who have failed or are unable to tolerate at least one oral bisphosphonate, or for whom oral bisphosphonate therapy is contraindicated, (including inability to swallow or to remain in an upright position after oral bisphosphonate administration), AND for: Treatment of postmenopausal women with osteoporosis at high risk for fracture (those who have had an osteoporotic fracture, or have multiple risk factors for fracture); OR Prevention of osteoporosis in persons receiving aromatase inhibitors (anastrozole, letrozole, exemestane); OR Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer; OR Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. The following statements were deleted from the When Denosumab Is Not Covered section: Bone loss associated with hormone-ablation therapy in breast cancer or prostate cancer and Use of denosumab is not approved for use in pregnant women, nursing mothers or pediatric patients. The statement: The same active ingredient (denosumab) is found in Prolia and XGEVA. Patient should not receive both drugs was added to Policy Guidelines. The statements Denosumab is not recommended for use in pediatric patients and There are no adequate and wellcontrolled studies of Prolia in pregnant women and nursing mothers. Prolia should be used during pregnancy and lactation only if the importance of the drug to Page 5 of 7
6 the mother justified the potential risk to the fetus/infant were also added to the Policy Guidelines. Codes J3490 and J3590 were added to the Billing/Coding section. (adn) 10/11/11 Specialty Matched Consultant Advisory Panel review 9/28/11. Policy accepted as written. (adn) 10/25/11 When Denosumab Is Covered section revised to clarify requirement for oral biphosphonate. (adn) 1/1/12 Code C9272 deleted and replaced with J0897 in the Billing/Coding section. (adn) 10/30/12 References updated. Specialty Matched Consultant Advisory Panel review 9/21/12. Added the following clinical indication to the When Covered section: Prolia may also be considered medically necessary as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. (sk) 7/16/2013 Medical Director review. References updated. Added the following clinical indication to the When Covered section: Xgeva may be considered medically necessary for treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity." (sk) 11/26/13 Specialty Matched Consultant Advisory Panel review 9/18/13. No change to Policy statement. (sk) 10/14/14 Reference updated. Specialty Matched Consultant Advisory Panel review 9/30/14. No change to Policy statement. (sk) 12/30/14 Reference updated. Added the following clinical indication to the When Covered section: Xgeva may be considered medically necessary for treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. Dosage forms and strengths information added to Description section. (sk) 10/30/15 References updated. Specialty Matched Consultant Advisory Panel review 9/30/15. (sk) 7/1/16 The wording in the When denosumab is covered section was revised. The statement regarding oral biphosphonate therapy was removed from the first paragraph and added to the first bulleted statement so that it now reads: Treatment of postmenopausal women with osteoporosis at high risk for fracture (those who have had an osteoporotic fracture or have multiple risk factors for fracture) AND who have failed or are unable to tolerate at least one oral bisphosphonate OR for whom oral bisphosphonate therapy is contraindicated (including inability to swallow or to remain in an upright position after oral bisphosphonate administration). (an) 9/30/16 Added ICD-10 diagnoses codes to Billing/Coding section. Medical Director review 9/2016. Notification given 9/30/16 for effective date 12/30/16. (lpr) 12/30/16 Added HCPCS codes S0353,S0354 and ICD10 codes M81.0, M81.8, T50.905, Z79.811, Z to Billing/Coding section. Deleted HCPCS codes J3490, J3590. Notification given 12/30/16 for effective date 4/1/2017. (lpr) 2/24/17 Added the following statement to When Covered section: Use of Denosumab may be considered medically necessary for clinical indications not listed above when the drug is prescribed for the treatment of cancer either: In accordance with FDA label (when clinical benefit has been established, see Policy Guidelines); OR In accordance with specific strong Page 6 of 7
7 endorsement or support by nationally recognized compendia, when such recommendation is based on strong/high levels of evidence, and/or uniform consensus of clinical appropriateness has been reached. Under When Not Covered section, added the statement Denosumab is considered investigational for cancer indications when criteria is not met regarding FDA labeling OR strong endorsement/support by nationally recognized compendia, as stated under When Denosumab is covered. Added the following statements under Policy Guidelines section: 1)Drugs prescribed for treatment of cancer in accordance with FDA label may be considered medically necessary when clinical benefit has been established, and should not be determined to be investigational as defined in Corporate Medical Policy, Investigational (Experimental) Services. 2) Please refer to CMP Investigational (Experimental) Services for a summary of evidence standards from nationally recognized compendia. Senior Medical Director review 2/2017. Remains on notice. Effective date 4/1/17. (lpr) 10/13/17 Specialty Matched Consultant Advisory Panel review 9/27/2017. No change to policy statement. (an) Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically. Page 7 of 7
PROLIA: Medical Coverage Policy Denosumab (Prolia and. Xgeva) EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Denosumab (Prolia and Xgeva) EFFECTIVE DATE: 11 01 2016 POLICY LAST UPDATED: 12 19 2017 OVERVIEW Prolia (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis
More informationCorporate Medical Policy Cellular Immunotherapy for Prostate Cancer
Corporate Medical Policy Cellular Immunotherapy for Prostate Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cellular_immunotherapy_for_prostate_cancers 6/2010 8/2017 8/2018
More informationPrior Authorization Required: Yes as shown below
PROLIA, XGEVA (denosumab) MB9409 Covered Service: Prior Authorization Required: Additional Information Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Yes as shown below Must be
More informationXgeva. Xgeva (denosumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.18 Subject: Xgeva Page: 1 of 5 Last Review Date: March 16, 2018 Xgeva Description Xgeva (denosumab)
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationXgeva. Xgeva (denosumab) Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.18 Subject: Xgeva Page: 1 of 5 Last Review Date: December 3, 2015 Xgeva Description Xgeva (denosumab)
More informationCorporate Medical Policy
White Blood Cell Growth Factors Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: white_blood_cell_growth_factors 9/2016 4/2017 4/2018 6/2017 Description of
More informationCorporate Medical Policy
Corporate Medical Policy Pertuzumab for Treatment of Malignancies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pertuzumab_for_treatment_of_malignancies 2/2013 4/2017 4/2018 6/2017
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: belimumab_benlysta 6/2011 2/2018 2/2019 3/2018 Description of Procedure or Service Belimumab (Benlysta) is
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gastric_electrical_stimulation 9/2003 5/2017 5/2018 5/2017 Description of Procedure or Service Gastric electrical
More informationcryosurgical_ablation_of_miscellaneous_solid_tumors 1/2007 5/2017 5/2018 5/2017
Corporate Medical Policy Cryosurgical Ablation of Miscellaneous Solid Tumors Other File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cryosurgical_ablation_of_miscellaneous_solid_tumors
More informationCorporate Medical Policy
Corporate Medical Policy Insulin Therapy, Chronic Intermittent Intravenous (CIIIT) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: insulin_therapy_chronic_intermittent_intravenous
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationCorporate Medical Policy
Corporate Medical Policy Rituximab for the Treatment of Rheumatoid Arthritis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: rituximab_for_the_treatment_of_rheumatoid_arthritis 4/2008
More informationCorporate Medical Policy
Corporate Medical Policy Proteomics-based Testing Related to Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomics_based_testing_related_to_ovarian_cancer 7/2010
More informationCorporate Medical Policy
Corporate Medical Policy Diagnosis and Treatment of Sacroiliac Joint Pain File Name: Origination: Last CAP Review: Next CAP Review: Last Review: diagnosis_and_treatment_of_sacroiliac_joint_pain 8/2010
More informationDENOSUMAB (PROLIA & XGEVA )
DENOSUMAB (PROLIA & XGEVA ) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 306.3 T2 Effective Date: July 2, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationCorporate Medical Policy
Corporate Medical Policy Serum Biomarker Human Epididymis Protein 4 (HE4) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: serum_biomarker_human_epididymis_protein_4_(he4) 1/2010
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testing_serum_vitamin_d_levels 9/2015 2/2017 2/2018 2/2017 Description of Procedure or Service Vitamin D,
More informationDescription of Procedure or Service. Policy. Benefits Application
Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer
More informationCorporate Medical Policy
Corporate Medical Policy Cryosurgical Ablation of Primary or Metastatic Liver Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cryosurgical_ablation_of_primary_or_metastatic_liver_tumors
More informationClinical Policy: Denosumab (Prolia, Xgeva) Reference Number: CP.PHAR.58
Clinical Policy: (Prolia, Xgeva) Reference Number: CP.PHAR.58 Effective Date: 03/11 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: renal_kidney_transplantation 4/1980 4/2017 4/2018 4/2017 Description of Procedure or Service A kidney transplant,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testing_serum_vitamin_d_levels 9/2015 2/2018 2/2019 2/2018 Description of Procedure or Service Vitamin D,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Prolia, Xgeva) Reference Number: CP.PHAR.58 Effective Date: 03.01.11 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationCorporate Medical Policy
Corporate Medical Policy Multigene Expression Assay for Predicting Recurrence in Colon File Name: Origination: Last CAP Review: Next CAP Review: Last Review: multigene_expression_assay_for_predicting_recurrence_in_colon_cancer
More informationCorporate Medical Policy Investigational (Experimental) Services
Corporate Medical Policy Investigational (Experimental) Services File Name: Origination: investigational_(experimental)_services 1/1996 Description of Procedure or Service BCBSNC defines the terms "investigational"
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Head and Neck File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_head_and_neck
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor_treatment_fields_therapy 9/2013 11/2017 11/2018 6/2018 Description of Procedure or Service Tumor-treatment
More informationtens_(transcutaneous_electrical_nerve_stimulator) 7/ / / /2014 This policy is NOT effective until January 13, 2015
Corporate Medical Policy TENS (Transcutaneous Electrical Nerve Stimulator) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tens_(transcutaneous_electrical_nerve_stimulator) 7/1982
More informationCorporate Medical Policy Transanal Endoscopic Microsurgery (TEMS)
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: transanal_endoscopic_microsurgery_(tems) 6/2008 11/2018 11/2019 11/2018 Description of Procedure or Service
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationCorporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma
Corporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor-treatment_fields_therapy_for_glioblastoma 9/2013 11/2017
More informationCorporate Medical Policy
Corporate Medical Policy Chelation Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chelation_therapy 12/1995 2/2017 2/2018 2/2017 Description of Procedure or Service Chelation
More informationCorporate Medical Policy
Corporate Medical Policy Treatment for Severe Primary IGF-1 Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: treatment_for_severe_igf-1_deficiency 2/2006 7/2017 7/2018
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: baroreflex_stimulation_devices 9/2011 4/2018 4/2019 4/2018 Description of Procedure or Service Baroreflex
More informationCorporate Medical Policy
Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate
More informationCorporate Medical Policy
Corporate Medical Policy Brachytherapy, Intracavitary Balloon Catheter for Brain Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_intracavitary_balloon_catheter_for_brain_cancer
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: esophageal_ph_monitoring 4/2011 5/2017 5/2018 5/2017 Description of Procedure or Service Acid reflux is the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Prolia, Xgeva) Reference Number: CP.PHAR.58 Effective Date: 03.01.11 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: charged_particle_radiotherapy 3/12/96 5/2017 5/2018 5/2017 Description of Procedure or Service Charged-particle
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: immune_cell_function_assay 11/2009 3/2017 3/2018 1/2018 Description of Procedure or Service Careful monitoring
More informationCorporate Medical Policy
Corporate Medical Policy Transtympanic Micropressure Applications as a Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: transtympanic_micropressure_applications_as_a_treatment_of_menieres_disease
More informationCorporate Medical Policy Automated Percutaneous and Endoscopic Discectomy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: percutaneous_discectomy 9/1991 5/2017 5/2018 5/2017 Description of Procedure or Service Surgical management
More informationCorporate Medical Policy
Corporate Medical Policy Small Bowel, Small Bowel with Liver, or Multivisceral Transplant File Name: Origination: Last CAP Review: Next CAP Last Review: small_bowel_liver_and_multivisceral_transplant 2/1996
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationCorporate Medical Policy
Corporate Medical Policy Dopamine Transporter Imaging with Single Photon Emission File Name: Origination: Last CAP Review: Next CAP Review: Last Review: dopamine_transporter_imaging_with_single_photon_emission_computed_tomography
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: heart_lung_transplantation 5/1985 6/2018 6/2019 6/2018 Description of Procedure or Service Combined heart/lung
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PROLIA, XGEVA 37012 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request for prior authorization. All requests
More informationCorporate Medical Policy
Corporate Medical Policy Pancreas Transplant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pancreas_transplant 1/2000 5/2017 5/2018 8/2017 Description of Procedure or Service Transplantation
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation in the Treatment of Germ File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_in_the_treatment_of_germ_cell_tumor
More informationCorporate Medical Policy
Corporate Medical Policy Ovarian, Internal Iliac and Gonadal Vein Embolization, Ablation and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ovarian_and_internal_iliac_vein_embolization
More informationCorporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
More informationCorporate Medical Policy
Corporate Medical Policy Biofeedback as a Treatment of Pain File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Biofeedback_as_a_treatment_of_pain 2/2017 5/2018 5/2019 5/2018 Description
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationCorporate Medical Policy
Corporate Medical Policy Quantitative Electroencephalography as a Diagnostic Aid for Attention File Name: Origination: Last CAP Review: Next CAP Review: Last Review: quantitative_electroencephalography_as_a_diagnostic_aid_for_adhd
More informationCorporate Medical Policy
Corporate Medical Policy Breast Brachytherapy for Accelerated Partial Breast Radiotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: breast_brachytherapy_for_accelerated_partial_breast_radiotherapy
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: occipital_nerve_stimulation 8/2010 5/2017 5/2018 5/2017 Description of Procedure or Service Occipital nerve
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nerve_fiber_density_testing 2/2010 10/2016 10/2017 10/2016 Description of Procedure or Service Skin biopsy
More informationCorporate Medical Policy
Corporate Medical Policy Repository Corticotropin (H.P. Acthar Gel) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: repository_corticotropin 7/2012 5/2018 5/2019 5/2018 Description
More informationCorporate Medical Policy
Corporate Medical Policy Saturation Biopsy for Diagnosis, Staging, and Management of Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: saturation_biopsy_for_diagnosis_ staging_and_management_of_prostate_cancer
More informationCorporate Medical Policy Intracellular Micronutrient Analysis
Corporate Medical Policy Intracellular Micronutrient Analysis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intracellular_micronutrient_analysis 6/2011 3/2017 3/2018 3/2017 Description
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: somatostatin_analogs 7/2016 7/2017 7/2018 7/2017 Description of Procedure or Service Somatostatin, a hypothalamic
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: facet_joint_denervation 6/2009 4/2017 4/2018 4/2017 Description of Procedure or Service Facet joint denervation
More informationCorporate Medical Policy Chelation Therapy
Corporate Medical Policy Chelation Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chelation_therapy 12/1995 2/2015 2/2016 2/2015 Description of Procedure or Service Chelation
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: bronchial_thermoplasty 10/2010 3/2018 3/2019 3/2018 Description of Procedure or Service Bronchial thermoplasty
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: surgical_deactivation_of_migraine_headache_trigger_sites 10/2012 5/2017 5/2018 5/2017 Description of Procedure
More informationCorporate Medical Policy
Corporate Medical Policy Ultrasound Accelerated Fracture Healing Device File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ultrasound_accelerated_fracture_healing_device 12/1994 2/2017
More informationCorporate Medical Policy
Corporate Medical Policy Non-Pharmacologic Treatment of Rosacea File Name: Origination: Last CAP Review: Next CAP Review: Last Review: non-pharmacologic_treatment_of_rosacea 8/2005 11/2017 11/2018 11/2017
More informationCorporate Medical Policy
Corporate Medical Policy TENS (Transcutaneous Electrical Nerve Stimulator) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tens_(transcutaneous_electrical_nerve_stimulator) 7/1982
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: exhaled_nitric_oxide_measurement 2/2009 3/2018 3/2019 3/2018 Description of Procedure or Service Asthma is
More informationCorporate Medical Policy
Corporate Medical Policy Axial Lumbosacral Interbody Fusion File Name: Origination: Last CAP Review: Next CAP Review: Last Review: axial_lumbosacral_interbody_fusion 6/2009 10/2017 10/2018 10/2017 Description
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: vagus_nerve_stimulation 6/1998 5/2017 5/2018 5/2017 Description of Procedure or Service Stimulation of the
More informationCorporate Medical Policy
Corporate Medical Policy Computer-Aided Evaluation of Malignancy with MRI of the Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: computer_aided_evaluation_of_malignancy_with_mri_of_the_breast
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_autoimmune_diseases
More informationCorporate Medical Policy
Corporate Medical Policy Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: laboratory_and_genetic_testing_for_use_of_5-fluorouracil_in_patients_with_cancer
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Abdomen and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: digital_breast_tomosynthesis 3/2011 6/2016 6/2017 11/2016 Description of Procedure or Service Conventional
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2018 10/2019 10/2018 Description of Procedure or Service Spinal muscular atrophy
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: electrodiagnostic_studies 2/2008 10/2017 10/2018 10/2017 Description of Procedure or Service Electrodiagnostic
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Passive Motion in the Home Setting File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_passive_motion_in_the_home_setting 9/1993 6/2018
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationCorporate Medical Policy
Corporate Medical Policy Viscocanalostomy and Canaloplasty File Name: Origination: Last CAP Review: Next CAP Review: Last Review: viscocanalostomy_and_canaloplasty 11/2011 6/2017 6/2018 6/2017 Description
More informationCorporate Medical Policy
Corporate Medical Policy Common Genetic Variants to Predict Risk of Nonfamilial Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: common_genetic_variants_to_predict_risk_of_nonfamilial_breast_cancer
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: dynamic_posturography 9/1990 2/2018 2/2019 2/2018 Description of Procedure or Service Dynamic posturography
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: capsule_endoscopy_wireless 5/2002 5/2016 5/2017 11/2016 Description of Procedure or Service Wireless capsule
More informationCorporate Medical Policy
Corporate Medical Policy Chelation Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chelation_therapy 12/1995 2/2018 2/2019 2/2018 Description of Procedure or Service Chelation
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationCorporate Medical Policy Septoplasty
Corporate Medical Policy Septoplasty File Name: Origination: Last CAP Review: Next CAP Review: Last Review: septoplasty 4/1999 8/2018 8/2019 8/2018 Description of Procedure or Service There are many potential
More informationCorporate Medical Policy
Corporate Medical Policy Urinary Tumor Markers for Bladder Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: urinary_tumor_markers_for_bladder_cancer 5/2011 11/2017 11/2018
More informationCorporate Medical Policy Electrocardiographic Body Surface Mapping
Corporate Medical Policy Electrocardiographic Body Surface Mapping File Name: Origination: Last CAP Review: Next CAP Review: Last Review: eletrocardiographic_body_surface_mapping 6/2009 10/2016 10/2017
More informationCorporate Medical Policy Genetic Testing for Breast and Ovarian Cancer
Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017
More informationSubject: Denosumab (Prolia ; Xgeva ) Injection
09-J1000-25 Original Effective Date: 08/15/10 Reviewed: 03/14/18 Revised: 12/15/18 Next Review: 01/09/19 Subject: Denosumab (Prolia ; Xgeva ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION,
More information